Eligibility Non-Small Cell Lung Cancer NCT02468661

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
locally advanced or metastatic nsclc
Description

ID.1

Data type

boolean

egfr mutation (l858r and /or ex19del)
Description

ID.2

Data type

boolean

cmet amplification by fish (gcn ≥ 6),
Description

ID.3

Data type

boolean

acquired resistance to egfr tki (1st or 2nd génération)
Description

ID.4

Data type

boolean

ecog performance status (ps) ≤ 1.
Description

ID.5

Data type

boolean

Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with 3rd generation tki
Description

ID.6

Data type

boolean

phaseii : prior treatment with any of the following agents:
Description

ID.7

Data type

boolean

crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
Description

ID.8

Data type

boolean

concomitant egfr tki and platinum based chemotherapy as first line regimen.
Description

ID.9

Data type

boolean

platinum-based chemotherapy as first line treatment
Description

ID.10

Data type

boolean

Similar models

Eligibility Non-Small Cell Lung Cancer NCT02468661

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
locally advanced or metastatic nsclc
boolean
ID.2
Item
egfr mutation (l858r and /or ex19del)
boolean
ID.3
Item
cmet amplification by fish (gcn ≥ 6),
boolean
ID.4
Item
acquired resistance to egfr tki (1st or 2nd génération)
boolean
ID.5
Item
ecog performance status (ps) ≤ 1.
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
prior treatment with 3rd generation tki
boolean
ID.7
Item
phaseii : prior treatment with any of the following agents:
boolean
ID.8
Item
crizotinib, or any other cmet inhibitor or hgf-targeting inhibitor.
boolean
ID.9
Item
concomitant egfr tki and platinum based chemotherapy as first line regimen.
boolean
ID.10
Item
platinum-based chemotherapy as first line treatment
boolean